Corbus Pharmaceuticals (NASDAQ:CRBP) Now Covered by B. Riley

Key Points

• B. Riley has initiated coverage of Corbus Pharmaceuticals with a "buy" rating and a price target of $28.00, suggesting a potential upside of 187.18% from its current stock price.
• The company's stock has experienced a remarkable 342% year-to-date surge and has an average analyst rating of "Moderate Buy" with an average target price of $49.38.
• Despite strong interest from institutional investors who own 64.64% of the stock, Corbus reported a quarterly earnings miss with an EPS of ($1.39), falling short of the consensus estimate.

B. Riley started coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBP - Free Report) in a report released on Wednesday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $28.00 price objective on the biopharmaceutical company's stock. B. Riley also issued estimates for Corbus Pharmaceuticals' Q2 2025 earnings at ($1.63) EPS, Q3 2025 earnings at ($1.63) EPS, Q4 2025 earnings at ($1.63) EPS, FY2025 earnings at ($6.29) EPS, FY2026 earnings at ($5.49) EPS and FY2027 earnings at ($5.50) EPS.

CRBP has been the topic of several other reports. Lifesci Capital upgraded shares of Corbus Pharmaceuticals to a "strong-buy" rating in a report on Saturday, July 12th. Oppenheimer decreased their price objective on shares of Corbus Pharmaceuticals from $60.00 to $56.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Royal Bank Of Canada decreased their price objective on shares of Corbus Pharmaceuticals from $65.00 to $58.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Finally, HC Wainwright decreased their price objective on shares of Corbus Pharmaceuticals from $50.00 to $40.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. One investment analyst has rated the stock with a sell rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $49.38.

Corbus Pharmaceuticals Price Performance

NASDAQ CRBP traded up $0.04 on Wednesday, hitting $9.31. 122,153 shares of the stock were exchanged, compared to its average volume of 122,735. The business's fifty day moving average is $8.32 and its 200 day moving average is $7.85. Corbus Pharmaceuticals has a 52 week low of $4.64 and a 52 week high of $61.89. The company has a market capitalization of $113.95 million, a PE ratio of -2.21 and a beta of 3.20.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.26) by ($0.13). Analysts predict that Corbus Pharmaceuticals will post -4.23 EPS for the current fiscal year.

Institutional Investors Weigh In On Corbus Pharmaceuticals

A number of large investors have recently bought and sold shares of CRBP. Two Sigma Investments LP increased its holdings in Corbus Pharmaceuticals by 212.3% in the 4th quarter. Two Sigma Investments LP now owns 134,175 shares of the biopharmaceutical company's stock valued at $1,583,000 after buying an additional 91,205 shares during the period. Millennium Management LLC boosted its stake in shares of Corbus Pharmaceuticals by 215.0% in the 4th quarter. Millennium Management LLC now owns 386,653 shares of the biopharmaceutical company's stock valued at $4,563,000 after purchasing an additional 263,902 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of Corbus Pharmaceuticals by 46.8% in the 4th quarter. Deutsche Bank AG now owns 8,206 shares of the biopharmaceutical company's stock valued at $97,000 after purchasing an additional 2,616 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Corbus Pharmaceuticals in the 4th quarter valued at approximately $323,000. Finally, Northern Trust Corp boosted its stake in shares of Corbus Pharmaceuticals by 12.4% in the 4th quarter. Northern Trust Corp now owns 103,264 shares of the biopharmaceutical company's stock valued at $1,219,000 after purchasing an additional 11,400 shares in the last quarter. 64.64% of the stock is currently owned by institutional investors and hedge funds.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.